hcplive.com
Cure8 news brief
Guselkumab and Intestinal Stenosis in Crohn's Disease, With David Rubin, MD | HCPLive
Research and clinical trials
Guselkumab
Ustekinumab
IL-23 inhibitor
IL-12/23 inhibitor
Cramping
Nausea
Vomiting
Why This Matters
Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning for some people with Crohn’s disease.
Biomarker work suggesting which stenoses are likely to respond to medical therapy may help avoid unnecessary surgery or identify patients who need surgery sooner.
Who Should Pay Attention
Adults with moderately to severely active Crohn’s disease, especially patients and clinicians managing intestinal stenosis or considering biologic therapy; researchers interested in IBD fibrosis and translational biomarkers.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
GALAXI and GRAVITI pooled analyses presented at ACG 2026 report that guselkumab treatment was associated with improvement from non-passable to passable or no intestinal stenosis through 96 weeks in a subset of patients with moderately to severely active Crohn’s disease.
RNA sequencing of ileal biopsies in a GALAXI subset linked clinical stenosis improvement to reductions in inflammatory- and fibrosis-associated fibroblast gene modules after guselkumab; ustekinumab showed limited changes.
These are post hoc and translational analyses presented at a conference; the article cites phase 3 trial publications for full trial results.
Keep In Mind
These results are from post hoc analyses of phase 3 trials and conference presentations; biomarker/translational findings are preliminary. Patients with symptomatic stenosis requiring surgery were excluded from the trials, so findings may not apply to those with obstructive symptoms or fibrotic strictures requiring immediate intervention.
Source Details
Review the original publication for the complete reporting, methods, and context.
Phase 3 clinical trial
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationhcplive.com
AuthorsDavid Rubin, MD
Indexed viaGoogle News
Source typeWeb article
PublishedOct 19, 2026, 5:20 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Researchers are testing whether targeting fungi with fluconazole can boost how well IL-23 biologics work for Crohn’s disease — if positive, this could point to a new adjunctive strategy to improve responses to biologic...
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...
A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...